<DOC>
	<DOCNO>NCT01549158</DOCNO>
	<brief_summary>This randomize , open-label , blinded-endpoint , crossover , single dose study compare pharmacodynamics Torasemide-PR 10 mg , Torasemide-IR10 mg furosemide-IR 40 mg. 30 patient sexes CHF maximum imbalance 60:40 % either direction include study . Patients compensate heart failure , grade II III define European Society Cardiology , duration ≥ 3 month time inclusion document patient 's record patient previously require diuretic therapy . Principal variable efficiency sodium excretion assess ratio average drug-induced natriuresis average drug recover urine 24 hour . The difference efficiency 24 hour sodium excretion follow administration torasemide PR furosemide formally test mean Students t-test paired sample . The test two-sided 5 % significance level . Efficiency change time also assess , however subject formal statistical testing .</brief_summary>
	<brief_title>Single Dose Study Compare Pharmacodynamics Torasemide-PR 10 mg , Torasemide-IR 10 mg Furosemide-IR 40 mg Patients With Compensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Torsemide</mesh_term>
	<criteria>1 . Able understand nature study . 2 . Obtain sign informed consent form approve Ethics Committee hospital ( CEIC ) . 3 . Male female , ≥ 18 year time inform consent signature . 4 . Patients compensate heart failure , grade II III define European Society Cardiology , duration ≥ 3 month time inclusion document patient 's record patient previously require diuretic therapy . 5 . Patients stable heart failure drug therapy . Stable drug therapy define introduced new drug heart failure within 4 week prior inclusion . Drugs dos could adjust study exception diuretic 6 . Lab analysis result , vital sign ECG within normal range consider clinically significant investigator . 7 . For woman , patient must : postmenopausal ( ≥ 1 year ) sterilize , without risk become pregnant , lactating , negative pregnancy test study entry without intention become pregnant study course use effective contraception . Postmenopausal status define 12 consecutive month spontaneous amenorrhea confirm result follicle stimulate hormone ( FSH ) &gt; 40 mlU/mL least 6 month oophorectomy ( without hysterectomy ) document patient record . 8 . Body weight within normal range ( Quetelet 's index 19 30 ) express weight ( kg ) /height ( m2 ) . 1 . Hospitalization due heart failure , acute coronary syndrome , myocardial infarction , cardiac catheterization , revascularization , cardiac arrhythmia , transient ischemic attack stroke , cardiac arrhythmia within 6 week prior inclusion major surgery include cardiac thoracic within 8 week prior inclusion . 2 . Symptoms angina rest minimal activity ( class III IV , Canadian Cardiovascular Society ) . 3 . Severe aortic mitral stenosis clinically significant valvular heart disease lead surgery within 12 month inclusion . 4 . Hypertrophic obstructive cardiomyopathy , active myocarditis , constrictive pericarditis clinically significant congenital heart disease . 5 . If ventricular assist device , continuous inotropic therapy hospitalization consider necessary case refractory endstage heart failure . 6 . Implementation CRT within 3 month cardioverter defibrillator 4 week inclusion . 7 . High probability receive heart transplant within 6 month inclusion . 8 . Main organ transplant ( ex . lung , liver , kidney , heart , bone ) . 9 . Positive surface antigen hepatitis B , hepatitis C HIV know diagnosis AIDS . 10 . Medical history evidence drug alcohol abuse 3 month prior inclusion . 11 . Concomitant cardiovascular disease expect reduce life expectancy le one year . 12 . Scheduled routine iv infusion heart failure ( ex . inotropes , vasodilator , diuretic ) routine ultrafiltration . 13 . Digoxin therapy steady state ( approximately 6 hour postdose ) exceed 1.0 ng/mL inclusion . 14 . Chronic therapy antiarrhythmic , antiepileptic drug , eplerenone espironolactone except amiodarone betablockers . 15 . Current intake within 14 day prior inclusion potent inhibitor CYP2C9 16 . Current intake within 28 day prior inclusion potent inducer CYP2C9 . 17 . Participation , 60 day 5 half life precede inclusion study , clinical trial . 18 . Systolic blood pressure &gt; 150mm Hg diastolic blood pressure &gt; 95 mmHg , confirm 2 separate visit inclusion . 19 . Heart rate supine &gt; 100 beats/min 5 minute rest untreated symptomatic bradycardia within one month prior inclusion . 20 . Total bilirubin &gt; 1.5 time ULN , ALT AST &gt; 3 time ULN . 21 . Estimated GFR &gt; 30 ml/min/1.73 m2 calculate modification diet renal disease ( RD ) . 22 . Chronic treatment NSAIDs ( &gt; 7 day ) , except aspirin &lt; 325 mg dose . 23 . Uncontrolled insulindependent diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>loop diuretic</keyword>
	<keyword>torasemide prolonged release</keyword>
	<keyword>torasemide immediate release</keyword>
	<keyword>Sutril Neo</keyword>
	<keyword>pharmacodynamic profile Torasemide-PR</keyword>
</DOC>